Your browser doesn't support javascript.
loading
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy.
Dhiantravan, Nattakorn; Violet, John; Eapen, Renu; Alghazo, Omar; Scalzo, Mark; Jackson, Price; Keam, Simon P; Mitchell, Catherine; Neeson, Paul J; Sandhu, Shahneen; Williams, Scott G; Moon, Daniel; Lawrentschuk, Nathan; Azad, Arun; Hofman, Michael S; Murphy, Declan G.
Afiliação
  • Dhiantravan N; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbou
  • Violet J; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Eapen R; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Alghazo O; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Scalzo M; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Jackson P; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Keam SP; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia; Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Mitchell C; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Neeson PJ; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Sandhu S; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Williams SG; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Moon D; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Victoria, Australia.
  • Lawrentschuk N; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; EJ Whitt
  • Azad A; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Hofman MS; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbou
  • Murphy DG; Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia. Electron
Eur Urol Focus ; 7(2): 234-237, 2021 03.
Article em En | MEDLINE | ID: mdl-33172774
ABSTRACT
LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium-177-radiolabelled small molecule PSMA-617 in men with high-risk localised/locoregional advanced prostate cancer with high prostate-specific membrane antigen expression who are undergoing radical prostatectomy and pelvic lymph node dissection.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prostatectomia / Doenças Prostáticas Tipo de estudo: Guideline Limite: Humans / Male Idioma: En Revista: Eur Urol Focus Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prostatectomia / Doenças Prostáticas Tipo de estudo: Guideline Limite: Humans / Male Idioma: En Revista: Eur Urol Focus Ano de publicação: 2021 Tipo de documento: Article